Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Levels of 17β-hydroxysteroid dehydrogenase type 10 in CSF are not a valuable biomarker for multiple sclerosis

Z. Kristofikova, J. Ricny, D. Kaping, J. Klaschka, J. Kotoucova, A. Bartos,

. 2018 ; 12 (12) : 1331-1340. [pub] 20181206

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19034869
E-zdroje Online Plný text

NLK PubMed Central od 2015 do Před 1 rokem
ProQuest Central od 2007-06-01 do 2021-01-31
Health & Medicine (ProQuest) od 2007-06-01 do 2021-01-31
Public Health Database (ProQuest) od 2007-06-01 do 2021-01-31

Odkazy

PubMed 30520659
DOI 10.2217/bmm-2018-0061
Knihovny.cz E-zdroje

AIM: We aimed to characterize the role of mitochondrial 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) overexpression in multiple sclerosis (MS) and to evaluate its use as a biomarker. Materials & methods: We estimated levels of 17β-HSD10, amyloid β 1-42, cyclophilin D, 17β-HSD10-cyclophilin D complexes or 17β-HSD10-parkin complexes in cerebrospinal fluid (CSF) samples. RESULTS: The increase in 17β-HSD10 levels or in 17β-HSD10-parkin complexes and links to leukocytes were found only in relapsing-remitting MS. The sensitivity of the biomarker was 64%, the specificity equaled 60-63% compared with controls. CONCLUSION: Increased CSF levels of 17β-HSD10 in later stages of MS could be interpreted via its upregulation in demyelinated neuronal axons. CSF levels of 17β-HSD10 are not the valuable biomarker for the early diagnosis or for the progression of MS.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19034869
003      
CZ-PrNML
005      
20191011084637.0
007      
ta
008      
191007s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.2217/bmm-2018-0061 $2 doi
035    __
$a (PubMed)30520659
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kristofikova, Zdenka $u National Institute of Mental Health, 250 67 Klecany, Czech Republic.
245    10
$a Levels of 17β-hydroxysteroid dehydrogenase type 10 in CSF are not a valuable biomarker for multiple sclerosis / $c Z. Kristofikova, J. Ricny, D. Kaping, J. Klaschka, J. Kotoucova, A. Bartos,
520    9_
$a AIM: We aimed to characterize the role of mitochondrial 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) overexpression in multiple sclerosis (MS) and to evaluate its use as a biomarker. Materials & methods: We estimated levels of 17β-HSD10, amyloid β 1-42, cyclophilin D, 17β-HSD10-cyclophilin D complexes or 17β-HSD10-parkin complexes in cerebrospinal fluid (CSF) samples. RESULTS: The increase in 17β-HSD10 levels or in 17β-HSD10-parkin complexes and links to leukocytes were found only in relapsing-remitting MS. The sensitivity of the biomarker was 64%, the specificity equaled 60-63% compared with controls. CONCLUSION: Increased CSF levels of 17β-HSD10 in later stages of MS could be interpreted via its upregulation in demyelinated neuronal axons. CSF levels of 17β-HSD10 are not the valuable biomarker for the early diagnosis or for the progression of MS.
650    _2
$a 3-hydroxyacyl-CoA-dehydrogenasy $x mok mozkomíšní $7 D015094
650    _2
$a dospělí $7 D000328
650    _2
$a amyloidní beta-protein $x mok mozkomíšní $7 D016229
650    _2
$a biologické markery $x mok mozkomíšní $7 D015415
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a roztroušená skleróza $x mok mozkomíšní $7 D009103
650    _2
$a peptidové fragmenty $x mok mozkomíšní $7 D010446
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ricny, Jan $u National Institute of Mental Health, 250 67 Klecany, Czech Republic.
700    1_
$a Kaping, Daniel $u National Institute of Mental Health, 250 67 Klecany, Czech Republic.
700    1_
$a Klaschka, Jan $u Institute of Computer Science, Academy of Sciences, 182 07 Prague, Czech Republic.
700    1_
$a Kotoucova, Jolana $u National Institute of Mental Health, 250 67 Klecany, Czech Republic.
700    1_
$a Bartos, Ales $u National Institute of Mental Health, 250 67 Klecany, Czech Republic. Department of Neurology, Third Faculty of Medicine, University Hospital Kralovske Vinohrady, Charles University, 100 34 Prague, Czech Republic.
773    0_
$w MED00172897 $t Biomarkers in medicine $x 1752-0371 $g Roč. 12, č. 12 (2018), s. 1331-1340
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30520659 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191011085057 $b ABA008
999    __
$a ok $b bmc $g 1451529 $s 1073419
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 12 $c 12 $d 1331-1340 $e 20181206 $i 1752-0371 $m Biomarkers in medicine $n Biomark Med $x MED00172897
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace